|Bid||46.14 x 1000|
|Ask||47.47 x 1400|
|Day's Range||45.26 - 46.11|
|52 Week Range||40.00 - 47.47|
|Beta (3Y Monthly)||0.48|
|PE Ratio (TTM)||23.77|
|Forward Dividend & Yield||1.74 (3.86%)|
|1y Target Est||52.00|
Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
Takeda Pharmaceutical Co's experimental dengue vaccine was highly effective at preventing the mosquito-borne disease in a late stage study, but it failed to protect against one type of the virus in people with no prior exposure to dengue. Takeda's vaccine was 80.2% effective at preventing dengue among children and teens in the year after they got the shot, according to results of a Phase III study published in the New England Journal of Medicine on Wednesday. Sanofi's Dengvaxia - the world's first dengue vaccine - had demonstrated 59.2% overall efficacy in the first year of follow-up based on combined results from two late-stage trials.
*Oncology: New data from investigational isatuximab pivotal study for the treatment of relapsed/refractory multiple myeloma *Rare Blood Disorders: New data spanning extensive portfolio demonstrates scientific ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
PARIS, Nov. 4, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for use in adults 65 years of age and older. Fluzone® High-Dose (Influenza Vaccine) was approved by the FDA in 2009 as a trivalent influenza vaccine, including two influenza A strains and one influenza B strain. Fluzone High-Dose Quadrivalent contains an additional influenza B strain.
Sanofi S.A. is shelling out $315 million to settle claims it bungled the launch of a multiple sclerosis drug developed by the Cambridge-based subsidiary Genzyme.
"We know that living with type 1 diabetes means dealing with highs and lows in blood sugar, which are worrying and present substantial challenges for young people," said Prof. Dr. Thomas Danne, Director of the Department of General Pediatrics and Endocrinology/Diabetology at the Children's Hospital On the Bult, Hannover Medical School, Germany. The trial, EDITION JUNIOR, is the first randomized, controlled trial comparing Toujeo vs Gla-100 in this group of patients.
Bayer Shows Strength Across Portfolio as Litigation Concerns Continue Bayer BAYRY reported third-quarter results largely in line with our projections. We continue to view the company as undervalued, with the market attributing too much concern to the ongoing glyphosate litigation.
Over the last three years, MilliporeSigma has boosted job applications and retention at its Danvers site, in part by introducing ESL classes.
PARIS , Oct. 31, 2019 /PRNewswire/ -- Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q3 2019 Change Change at CER 9M 2019 Change Change at CER IFRS net sales reported €9,499m +1.1% -1.1% €26,518m +4.1% +2.2% IFRS ...
(Bloomberg) -- Sanofi’s key growth driver, a drug for eczema and asthma, helped the French pharma giant report earnings that beat analysts’ estimates in Paul Hudson’s first quarter as chief executive officer.Earnings excluding some items climbed 4.3% to 1.92 euros a share in the quarter. Analysts predicted earnings of 1.72 euros a share. The company reiterated its forecast of 5% growth for the year.Key InsightsSanofi’s new chief, who took the reins last month, will face questions on the future of the company’s consumer-health and diabetes units, R&D priorities and M&A plans. An experimental cancer combination was stopped in the quarter for efficacy reasons, along with an early-stage treatment for obesity and diabetes, Sanofi said. Hudson is expected to accelerate efforts to revamp the pipeline in the coming months.The hemophilia medicine Eloctate will be in focus after disappointing results pushed the drugmaker in July to curtail sales projections and announce a 1.8 billion-euro ($2 billion) charge.Market PerformanceThe stock rose as much as 1.7% in early Paris trading. The shares have gained about 12% so far this year, compared with a 20% gain in the Bloomberg Europe 500 Pharmaceuticals Index.Get MoreRead more details.See the statement.(Updates with share price in market performance section.)To contact the reporter on this story: James Paton in London at firstname.lastname@example.orgTo contact the editors responsible for this story: Eric Pfanner at email@example.com, Marthe Fourcade, Frank ConnellyFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Sanofi expressed confidence for the fourth quarter and confirmed its full-year objectives on Thursday after posting lower third-quarter sales, hit by a fall in revenue at its primary care and vaccines businesses. Shares in Sanofi were down 1.6% at 83.89 euros by 1430 GMT, underperforming a 0.16% drop in the wider market . "Focus remains on the Dec 10 capital markets day," Jefferies analysts wrote in a note to clients, at which the group's newly appointed chief executive Paul Hudson is expected to unveil Sanofi's middle and long term strategy.